Clinical Trial Update: Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors [Phase 2]

View source ↗

Summary

Ipsen-sponsored Phase 2 trial evaluating cabozantinib as second-line treatment for locally advanced or metastatic renal cell carcinoma with a clear-cell compone…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)

Snippet

Sponsor: Ipsen | Conditions: Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-12-19